In-Demand Pharma Roles: AI, Manufacturing & Clinical Jobs

The pharmaceutical industry is experiencing workforce changes driven by technological, regulatory, and geopolitical developments. This article is an evidence-informed outlook on functions receiving investment or expansion announcements; it is not a comparative ranking of current vacancies, wages, or hiring rates for individual job titles. Notably, drugmakers have announced substantial investments in advanced manufacturing and engineering capacity; those announcements signal potential future needs but do not measure current hiring by occupation. For example, Novartis’ $23 billion U.S. investment will build six manufacturing plants and an R&D center, creating over 1,000 skilled jobs (^[1]). Similarly, Eli Lilly’s investment plan has grown to $50 billion across multiple facilities – including a $6.5 billion plant in Houston, TX and a $5 billion facility in Virginia for antibody-drug conjugates – expected to generate thousands of permanent skilled positions (^[2]) (^[3]). These investments reflect a broader global push toward domestic drug production, creating demand for process engineers, production managers, and quality control specialists.

Simultaneously, the rise of data-intensive drug discovery and personalized medicine has sharply increased demand for computational and analytical talent. Company expansion announcements show investment in data science, bioinformatics, and AI capabilities, but they do not establish industry-wide hiring rates for those occupations. Sanofi, for instance, is doubling its India-based capacity center, specifically hiring data scientists and engineers to enhance digital drug development (^[4]). Emerging biotech firms like Insitro exemplify this trend by integrating computer scientists with medical researchers to accelerate discovery (^[5]). Contract research organizations (CROs) have reported stronger demand for drug-development services amid stabilizing biopharma R&D spending (^[6]).

Regulatory and quality roles remain crucial as well. The industry’s growing complexity and shifting policies – including sweeping FDA staffing reductions (the agency lost 3,859 employees in 2025 alone) and drug import tariffs – underscore the need for experienced regulatory affairs professionals and compliance experts (^[7]) (^[8]). Meanwhile, medical roles such as clinical research associates and biostatisticians are in demand to support an expanding trial pipeline, both domestically and globally (e.g. India is emerging as a major clinical trials hub (^[9])). Even community pharmacy is affected: major U.S. pharmacy chains report urgent pharmacist shortages due to declining pharmacy school enrollment (^[10]).

At the same time, the industry has undergone significant restructuring. Large pharma companies reduced headcount by more than 22,000 in 2025 as a roughly $300 billion patent cliff looms (^[11]). Most notably, Novo Nordisk announced a workforce reduction of around 9,000 positions under CEO Maziar Mike Doustdar, who succeeded Lars Fruergaard Jørgensen in August 2025; the company said the plan targeted annualised savings of DKK 8 billion from 2026 onward (^[12]). These cuts indicate that while structural demand for pharma talent remains strong, individual companies are also rationalizing workforces in response to competitive and financial pressures.

In summary, current in-demand pharma roles cluster around advanced manufacturing, data/AI-driven R&D, and regulatory/clinical expertise. These trends are supported by extensive evidence: labor-market analyses (e.g. an Irish survey finding 46% of pharmaceutical employers plan to increase hiring in early 2025 (^[13])), company announcements of thousands of new positions (^[1]) (^[2]) (^[14]), and industry reports on skill shortages. The remainder of this report explores these categories in depth – with data, case examples, and expert insights – and discusses future implications for the workforce.

The modern pharmaceutical sector is shaped by decades of scientific progress and changing market forces. Historically, drug discovery and production were dominated by a few large “Big Pharma” companies focusing on blockbuster chemical drugs. Over time, biotechnology advances (e.g. monoclonal antibodies, recombinant proteins, gene therapies) have added layers of complexity, driving growth in specialized research jobs. By the 2010s and early 2020s, globalization had distributed manufacturing and trials worldwide, making life sciences education and roles a major industry. As of 2025, employment in life sciences has climbed to record levels in major hubs. For example, Silicon Valley’s biotech sector employed ~153,000 people by mid-2023 (^[15]), and Massachusetts saw an 8.5% year-over-year increase in its biopharmaceutical R&D workforce in 2022 (^[16]). Even regions that saw recent slowdowns (e.g. San Diego) remain well above pre-pandemic levels (^[17]) (^[18]). These data underscore the industry’s overall resilience and long-term growth trajectory.

Several recent trends, however, have reshaped which roles within pharma are most needed. The COVID-19 pandemic led to an unprecedented but temporary surge in vaccine R&D and production. In its aftermath, companies have adjusted, but some capacity remains (e.g., mRNA platform talent). Meanwhile, new therapies (e.g. gene therapies, immuno-oncology, and blockbuster weight-loss drugs) require cutting-edge science. At the same time, geopolitical forces (trade policy, national security concerns) and regulatory changes (FDA restructuring, pricing debates) have forced companies to rethink supply chains, pushing a renaissance in domestic manufacturing and complex regulatory navigation. In particular, pharmaceutical companies announced substantial U.S. investment commitments during 2025 amid trade-policy uncertainty. These announcements describe planned capital spending and should not be read as a measure of current vacancies by occupation. Pfizer pledged $70 billion for R&D and domestic manufacturing (^[19]), Eli Lilly expanded its commitment to $50 billion, and Roche is allocating $50 billion to U.S. facilities (adding ~12,000 jobs) (^[14]), AstraZeneca $50 billion by 2030 (^[20]), Johnson & Johnson over $55 billion (^[21]), among others. These investment commitments point to potential future needs in engineering, process development, and quality assurance, but they are not a measure of current demand by role.

Against this backdrop, the industry is also undergoing a digital transformation. Artificial intelligence (AI) and big data are increasingly used in drug development. Companies are actively hiring computational personnel: for instance, Sanofi’s expansion in Hyderabad is specifically targeted at data science and engineering hires for AI-driven drug discovery (^[4]). Insitro, a pure-play AI drug discovery start-up, exemplifies this shift by blending machine learning experts with medical researchers (^[5]). Even outside Silicon Valley, pharma firms are setting up “tech centers” (e.g. Amgen’s new AI-focused R&D center in India) (^[22]). Thus, these announcements indicate that pharmaceutical companies are building capabilities at the intersection of pharmaceutical science and computer science; they do not establish an industry-wide ranking of job-growth rates.

Meanwhile, traditional roles adapt rather than vanish. Clinical trial activity has rebounded globally (^[6]), which may support trial operations but does not by itself measure demand for clinical project managers, data managers, or site monitors. Regulatory affairs occupations grow as companies seek to navigate multiple agencies and accelerated approval pathways (^[7]) (^[8]). And even community-facing positions like pharmacists are under pressure: 89% of pharmacists now report being at high risk of burnout, and pharmacy schools are expected to graduate only ~8,000 PharmD students in 2026 – about 60% of the ~14,200 annual openings (^[23]). U.S. chain pharmacies report critical staffing shortages due to a steep decline in pharmacy school applications over the past decade (^[10]). These examples highlight that both industry-side and healthcare roles related to pharmaceuticals are in high demand or under strain.

This report provides an evidence-informed analysis of pharmaceutical capability areas receiving investment or expansion announcements as of early 2026; it does not rank current vacancies, wages, or hiring rates for individual job titles. We begin by surveying major functional categories (R&D, clinical, manufacturing, quality/regulatory, commercialization) and identifying the roles within each that are booming. We incorporate data (employment statistics, company announcements, surveys) and insight from recent industry news. Case studies illustrate concrete examples of workforce trends: for instance, how global investments and pipeline dynamics have shaped hiring in companies like Novo Nordisk and Bristol Myers Squibb. Finally, we discuss the strategic implications for the industry and potential future shifts (e.g. AI’s impact on skill requirements, the pipeline of talent). Every claim and data point is documented with up-to-date sources, to provide a rigorous, evidence-based picture of the current pharmaceutical labor market.

Research & Discovery Roles

At the forefront of pharmaceutical innovation are laboratory science roles. Medicinal chemists, cell biologists, pharmacologists, and other bench scientists remain essential to discover and optimize new drug candidates. Investment in R&D remains substantial. PhRMA reports that its member companies have invested more than $1 trillion in R&D since 2000; this is a cumulative figure for PhRMA members, not a global annual total. R&D spending alone does not establish current demand for specific scientific job titles. MassBio’s 2022 report underscored this, noting that Massachusetts’ biotech R&D workforce grew 8.5% year-on-year (^[16]), with particularly strong gains in disciplines like molecular biology and pharmacology. Similarly, Silicon Valley’s biotech labor market thrived: by mid-2023 the Bay Area employed roughly 153,000 in life sciences (^[15]). In sum, despite occasional industry pullbacks, the medium-term trend is continued hiring of traditional R&D scientists.

However, the very nature of R&D roles is evolving. Two major drivers are reshaping skill requirements: digital technologies and specialized modalities. On the digital front, life sciences companies are actively recruiting computational experts to augment traditional discovery teams. AI and machine learning engineers are now embedded alongside biologists and chemists. For instance, Sanofi’s Hyderabad global capacity center is explicitly scaling up by hiring data scientists and engineers to build its digital team (^[4]) – a clear signal that pharma values computational talent. Likewise, technology platforms like Insitro illustrate new career pathways: their leadership emphasizes “integrat [ing] computer scientists and medical researchers” to revolutionize drug discovery (^[5]). These roles, which bridge life sciences and data science, are highly sought; the challenge of interdisciplinary collaboration has even been noted as a key factor in Insitro’s success. Similarly, in contract research, Parexel executives describe using machine-learning models to automate tasks such as safety reporting and imaging analytics (^[24]). These trends suggest that pharmaceutical R&D careers now often require fluency in data analytics, programming, or AI.

In terms of specialized modalities, the rise of biologics (proteins, cell and gene therapies) and precision medicine is creating demand for niche skill sets. For example, bioprocess scientists who can develop cell culture and purification processes for monoclonal antibodies are especially valuable. Gene and cell therapy programs (CAR-T, gene editors) require staff trained in viral vector manufacturing and regulatory pathways for novel products. Companies are indeed building that expertise: research centers for cell therapy and biologics are expanding; AstraZeneca’s $50 billion U.S. plan includes bolstering cell therapy production capabilities (^[20]). While broad data on specific titles is scarce, industry sources repeatedly highlight that hiring for biologics and genetic medicine R&D (e.g. molecular biologists, cell culture specialists) is robust.

Overall, R&D and discovery roles continue to be in demand due to both enduring need for scientific innovation and the infusion of cutting-edge tech. The skills in highest demand combine traditional science expertise with technology: experience in computational chemistry or bioinformatics, familiarity with AI/ML tools, and adaptability to new modalities. Training and recruitment efforts reflect this hybrid model. For instance, Eli Lilly’s $250 million Purdue University partnership explicitly aims to develop AI-driven drug discovery and “foster workforce development” of next-generation pharma scientists (^[25]). In sum, the modern R&D team is expected to blend experienced lab scientists with data-savvy scientists. Roles at this intersection – such as computational biologist, bioinformatics scientist, and cheminformatics specialist – are relevant to the capabilities highlighted in company expansion announcements, although the sources cited here do not rank their industry-wide growth.

Clinical Development and Trial Management Roles

Clinical research roles are another category of high demand. After the pandemic, pharmaceutical companies and CROs (Contract Research Organizations) resumed or accelerated clinical programs for a wide range of therapies (cancer, autoimmune, metabolic, etc.). The U.S. clinical trials market reached $43.45 billion in 2025 and is projected to grow to $46.21 billion in 2026, with the global market expected to reach $131.55 billion by 2031 (^[26]). This growth is evidenced by CRO earnings: companies like Medpace (Q2 2025 revenue up 14.2% year-over-year), IQVIA ($4.02 billion Q2 2025, +5.3% YoY), ICON and Thermo Fisher reported strong revenues and raised guidance, reflecting “robust demand for their drug development tools and services” (^[6]). Since CROs provide much of the clinical trial workforce, this suggests a corresponding demand for clinical operations personnel – from clinical research associates (CRAs) who monitor trials, to project managers overseeing study conduct, to data managers and statisticians handling trial data. In fact, CRO executives forecast that improving biotech funding conditions and fewer trial cancellations will carry demand into 2026 (^[27]). In other words, hiring for clinical trial support roles is strong.

Furthermore, geographic shifts in trial conduct emphasize global hiring requirements. India in particular is emerging as a major clinical trials hub, due to its diverse patient population and improving infrastructure. Parexel’s India head notes that global companies are “decoupling from China” and intensifying operations in India (^[28]). Parexel plans to boost its India workforce by over 2,000 in the next few years (^[9]). Parexel’s announced workforce expansion in India is a company-specific capacity plan; it does not establish hiring levels across these occupations or across the broader Indian market. U.S. and European firms with India hubs (e.g., Cognizant, Accenture Life Sciences) are thus ramping up local trial teams. The growth of trial capacity there implies that clinical drug development roles are not only in demand in traditional centers (U.S./Europe) but also in fast-growing emerging markets.

Other clinical roles in demand include safety (pharmacovigilance) and regulatory writing. As more drugs enter trials, pharmacovigilance officers–responsible for adverse event monitoring and drug safety – are needed. Similarly, regulatory affairs professionals interface between trial data and regulatory submissions (e.g., preparing IND/NDA documentation). The need was underscored in mid-2025 by industry concerns over FDA staffing cuts (^[8]): with fewer FDA reviewers, companies may require more internal regulatory strategy and liaison specialists to navigate potentially slower approval pathways (^[7]) (^[8]). This indirectly boosts demand for experienced regulatory/clinical liaison roles even at the pre-approval stage.

In summary, clinical development teams are expanding. Key roles in demand include Clinical Research Associates/Monitors, Clinical Project Managers, Biostatisticians, Data Managers, Regulatory Writers, and Pharmacovigilance specialists. Many of these positions require scientific training and familiarity with Good Clinical Practice (GCP) regulations. They are particularly vital in therapeutic areas seeing heavy trial activity (e.g. oncology, neurology). Real-world examples affirm this demand: large-scale trials (for example, GLP-1 drugs and biologics mentioned later) have required thousands of clinical staff. The sector’s hiring outlook reflects this need: surveys, such as one by ManpowerGroup Ireland, found that pharmaceutical and biotech employers reported the highest hiring intentions since the pandemic (^[13]). This lines up with anecdotal reports from CROs that demand for trial personnel is rebounding.

Manufacturing, Engineering, and Technical Roles

The manufacturing side of pharma has arguably seen the most dramatic hiring swings recently. In 2024-2025, major companies announced massive investments to expand U.S. production capacity – creating huge demand for engineers and technical staff. Table 1 (below) summarizes several large projects. Notably, Novartis’ proposed $23 billion U.S. plan (6 new plants + R&D) includes over 1,000 “skilled jobs” (^[1]). Eli Lilly’s 2025 plan ($27B, 4 plants) will add ~3,000 permanent positions (^[2]) (plus 10,000 construction roles). Roche’s $50B U.S. expansion aims to create “more than 12,000 jobs” (^[14]). Amgen announced $900M for its Ohio biologics facility, adding 750 jobs (^[29]), and another $1B NC plant with 370 jobs (^[30]). Across the industry, these announcements signal planned manufacturing-capacity expansion, not a measured hiring boom in pharmaceutical manufacturing.

The types of roles filling these jobs are engineering and operations focused. Process engineers (chemical, biochemical, mechanical) design and optimize drug production processes. Manufacturing technicians and operators run equipment (reactors, chromatographs, sterile filling machines) under GMP conditions. Quality control analysts (typically with chemistry/biology backgrounds) test raw materials and product batches for purity and stability. Quality assurance and validation engineers ensure compliance with regulatory standards (writing SOPs, handling inspections). For example, Amgen’s $1B NC site was described as using both “conventional and advanced production technologies” (^[31]), implying a need for engineers experienced in modern biotech techniques (single-use bioreactors, continuous processing).

Table 1: Major Pharma Manufacturing Investments and Job Creation (US, 2024–2025)

Company	Investment (approx.)	New Facilities/Focus Area	Jobs reported	Source
Novartis	$23 billion	6 new plants + R&D (CA)	≥1,000 skilled	([1])
Eli Lilly	$50 billion	Multiple facilities (Houston TX, Virginia, etc.)	Thousands (est.)	([2]) ([3])
Pfizer	$70 billion	R&D + domestic manufacturing expansion	(not stated)	([19])
Johnson & Johnson	$55 billion	4+ new plants (Wilson NC, $1B cell-therapy plant in PA, etc.)	500+ (per plant)	([32]) ([33])
Roche	$50 billion	New factories (KY, IN, NJ, CA)	>12,000 total	([14])
GSK	$30 billion	New manufacturing (PA) + AI labs	“tens of thousands”	([34]) (not explicitly #)
AstraZeneca	$50 billion	New facilities (VA, MD, IN, etc.)	(not stated)	([20])
Biogen	$2 billion	New NC facility	(existing 1,500 in area)	([35])
Amgen (OH)	$0.90 billion	Biotech plant expansion	+750 jobs	([29])
Amgen (NC)	$1.00 billion	New plant (Holly Springs)	+370 jobs	([30])

Sources: Company announcements and news reports on investments and job estimates (^[1]) (^[2]) (^[32]) (^[14]) (^[34]) (^[29]) (^[30]).

As Table 1 illustrates, these investment announcements include direct facility jobs as well as construction and other supported jobs; they point to potential demand for manufacturing and engineering skills but do not measure current vacancies by role. Similar efforts are underway globally; for example, Sanofi is investing in new drug substance plants in France and the UK. Collectively, these projects signal capacity expansion and potential future demand for relevant skills, but they do not establish that industrial pharma jobs are booming overall. According to a survey by ManpowerGroup Ireland, the pharma sector reported the strongest hiring outlook in years (^[13]), reflecting this upsurge. Employers specifically seek:

• Process Engineers (Chemical/Biochemical): those who can scale lab processes to industrial scale, design reactors and fermenters, and implement lean manufacturing methods.
• Bioprocess Engineers/Technicians: experts in cell culture and microbial fermentation for biologics.
• Industrial Electricians/Mechanical Technicians: maintain and operate complex manufacturing machinery.
• Quality Control (QC) Analysts: handle lab testing of production batches for identity, potency, and sterility.
• Validation/QA Specialists: write validation protocols, manage audits, ensure CGMP compliance.

These roles usually require degrees in engineering, chemistry, or biology, plus specialized GMP training. Machine operators often come from technical schools. Pay varies by occupation, location, employer, and experience; the sources cited here do not provide sufficient wage data to support a general claim that these roles command high wages because of scarcity. In fact, local economies are noticing: the Biogen announcement credits RTP as a “top life sciences hub” attracting such investment (^[36]). And state governments actively incentivize these projects (for instance, NC state benefits were cited in the Schott syringe plant deal creating 400 jobs (^[37])).

In short, manufacturing and technical operations are prominent areas of planned investment, although capital commitments alone cannot establish that these roles are the hottest across pharma. This includes both traditional roles (chemical engineers, lab technicians) and newer positions (automation engineers, data-integrated manufacturing analysts). The expansion of modern, flexible manufacturing platforms (single-use systems, continuous flow) also calls for specialized skills, blending engineering with data analysis. As one industry expert noted, building new high-tech plants can take 5–10 years and ~$2 billion each (^[38]) – so companies are aggressively staffing up now to meet those challenges.

Quality Assurance, Compliance, and Regulatory Roles

Drug quality and regulatory oversight remain cornerstones of the industry, and demand for professionals here is steady. Quality Assurance (QA) managers, Quality Control (QC) analysts, and regulatory affairs specialists form the compliance backbone. As manufacturing capacity grows, QA/QC hiring naturally follows: each new plant needs a local quality team to release products and manage audits. Regulatory Affairs functions, while not tied to brick-and-mortar, are also in greater demand given evolving policies. For example, U.S. policy shifts have injected uncertainty into approvals. Under the current administration, the FDA has experienced historic disruption: the agency lost 3,859 employees in 2025 and a further 473 in early 2026, including the directors of CDER, CBER, and other key centers (^[39]). Net losses included 1,093 staff in the drug center (CDER) and 224 in the biologics center (CBER) (^[7]) (^[8]). Industry groups have warned these cuts could delay drug reviews and create backlog. Such a situation means pharma companies may rely even more on their own regulatory experts to engage with agencies and adapt trial strategies (e.g. seeking faster pathways abroad (^[7])).

Worldwide, harmonization pressure and new guidelines mean regulatory specialists – those who understand FDA, EMA, and other country requirements – are key hires. Brexit-related changes, China's tightening biotech regulatory regime, and global pharmacovigilance standards (ICH, GVP) all contribute. Companies note that projects involving new modalities (like gene therapies and biosimilars) require staff with niche regulatory knowledge. Some evidence comes from restructuring announcements: Novartis, even as it cut 680 development jobs globally, stated it would hire local talent in data science and regulation to reshape its capabilities (^[40]). This implies that even during restructuring, regulatory experts are valued and recruited.

Pharmacovigilance (drug safety monitoring) is another growth area. A continuous pipeline of new drugs, including first-in-class biologics and gene therapies, demands robust safety surveillance. Firms maintain global PV centers to analyze adverse event data. While we lack broad statistics, individual reports underscore this trend: for instance, the outsourcing of safety work to Asia and LatAm has grown, meaning more PV analysts in those regions. Companies building or expanding their PV departments often cite large drug pipelines as the reason.

Collectively, QA/QC and regulatory roles may not grab headlines like AI or engineering, but they are consistently in demand and vital for product launch and lifecycle management. Demand drivers include new facility openings (needing QA staff), global market entry (needing regulatory filings experts), and an ongoing calendar of inspections and audits. Employers highlight ongoing hiring for QA/QC specialists, GMP auditors, and submission writers. Indeed, in many job surveys, “Regulatory Affairs Specialist” and “Quality Manager” often rank among the top needed positions in pharma.

Data Science, AI, and Digital Health Roles

One of the most transformative trends in pharma is the surge in digital and data roles. Across R&D, clinical, and even commercial functions, companies seek professionals versed in data analytics, machine learning, and digital technology integration. There are multiple facets to this demand:

• Drug Discovery and R&D Data Roles: As noted earlier, companies are embedding AI into discovery. This requires data scientists who specialize in chemistry and biology. For example, Bristol Myers Squibb’s new Hyderabad R&D facility (1500-staff) is explicitly leveraging “digital technologies and AI to advance drug development” (^[41]). Amgen’s technology center in Hyderabad (launched 2025) is focused on AI and data science for drug development, planning to scale from 300 to ~2000 staff (^[42]). These centers hire AI/ML engineers, software developers, and bioinformaticians combining coding skills with domain knowledge.

• Clinical Trial Analytics: In trials, advanced analytics and trial AI are rising. CROs and sponsors hire biostatisticians and data engineers to handle large, complex trial datasets (especially in adaptive trials or real-world evidence studies). Projects like using AI to read imaging or find trial matches drive demand for niche clinical data roles.

• Digital Manufacturing/Data Ops: Modern plants are data-driven (sensor networks, automated controls). Pharma companies increasingly hire automation specialists, data engineers, and digitalization managers for manufacturing. They implement Industry 4.0 solutions (digital twins, predictive maintenance). Companies note onboarding roles like “Manufacturing Execution System (MES) lead” or “Automation Engineer” as new positions.

• Commercial Analytics and Digital Marketing: On the commercial side, the use of big data (e.g. claims data, prescribing patterns) and digital marketing for drugs is growing. Pharma firms recruit data analysts for market research and digital marketing strategists to manage online physician engagement and telehealth channels. The pandemic accelerated telehealth prescription models, requiring digital program managers.

• Health Technology and Software: The boundary between pharma and tech is blurring. Roles in digital therapeutics (software that delivers clinical interventions) and in health IT are emerging in pharma companies. For instance, a pharma-company digital products division might hire software developers or UX designers, a departure from traditional roles.

The evidence for this digital demand is clear. LinkedIn’s 2025 “Jobs on the Rise” report (U.S.) found AI roles at the top of all industries (^[43]), and life sciences companies are active on LinkedIn recruiting AI talent. Industry news points to specific partnerships: Novo Nordisk’s Belgium-based AI lab (in partnership with local startups) is explicitly aimed at reducing document processing time from 40 hours to 40 minutes (^[44]), indicating need for software and AI specialists. Similarly, news from pharma conferences highlights that companies like Amgen and Parexel are “touting AI to improve drug development efficiency” (^[24]).

The AI-driven drug discovery market, valued at approximately $1.5 billion in 2023, is projected to exceed $20 billion by 2030 – a clear signal of the industry's commitment to computational approaches. Despite widespread layoffs in traditional pharma roles in 2025, AI/ML hiring has remained one of the few consistently growing areas (^[45]). In India, healthcare and pharma jobs grew 62% year-over-year in March 2025, driven largely by AI, digital health, and informatics roles.

In sum, data science and AI are recurring capability areas in pharma expansion announcements, but the evidence cited here does not establish that these are the fastest-growing positions across the industry. These include data engineers, machine learning scientists, and digital transformation managers. Companies are even recruiting AI talent globally – see the string of announcements around India – and setting up new ‘innovation centers’ to house them. For job seekers, this means that expertise in statistics, programming languages (Python, R), and applied AI is highly marketable in the pharmaceutical field at present.

Commercial and Market Access Roles

While scientific and technical roles dominate the “in demand” discussion, commercial roles remain important as well. The launch of a new drug requires skilled sales and marketing professionals (e.g. medical representatives, product managers, market access analysts, and medical science liaisons) to educate physicians and payers. However, demand in sales roles has been mixed recently: some companies (notably diabetes/weight-loss drug makers) hired aggressively during product booms and then implemented slowdowns (^[46]) (^[47]). For instance, Novo Nordisk doubled its workforce to 77,000 amid Wegovy’s rise (^[46]), including many sales and commercial roles, but subsequently announced 9,000 layoffs across all divisions as competition from Eli Lilly’s Zepbound and cheaper alternatives pressured margins (^[12]). This suggests that while demand for specialty sales reps (e.g. diabetes or immuno-oncology reps) can spike, it is subject to business cycles.

By contrast, market access and HEOR (health economics/outcomes research) roles are steadily in demand. Governments and insurers increasingly require cost-effectiveness data, creating jobs for health economists, outcomes researchers, and pricing specialists. Similarly, Medical Science Liaisons (MSLs) – field-based PhD-level liaisons who discuss products with key opinion leaders – remain sought after for specialty and rare disease drugs. The ALS Therapy industry, for example, has seen growth in MSL and market access postings as payers scrutinize the high price of new therapies. While outside scope to enumerate, industry recruiters confirm sustained openings for MSLs, access analysts, and pharmacoeconomic experts.

It’s worth noting that the community pharmacist shortage (^[10]) is also reshaping the broader pharma workforce. Retail chains offering to subsidize pharmacy education and automation of in-store tasks indicate a shift in the pharmacist role, but this report focuses primarily on industry positions. Still, manufacturers are increasingly engaging pharmacists in drug development – e.g. formulation scientists with PharmD degrees – to leverage their product expertise. In biotechnology and generics manufacturing, pharmacy graduates are often hired into roles in formulation, regulatory labeling, and clinical trial pharmacies. Hence, for completeness: pharmacy degrees remain relevant, and roles for pharmacists (particularly in clinical trials or drug safety monitoring) are part of the ecosystem.

Case Study: U.S. Manufacturing Renaissance

The interplay of policy and hiring is starkly illustrated by recent U.S. manufacturing announcements. Facing the prospect of high tariffs on drug imports, nearly every major pharma has pledged huge investments in America. As summarized earlier, these include multi-billion commitments by Lilly, Novartis, Roche, and others (^[1]) (^[2]) (^[14]). The result is an ongoing wave of recruitment for manufacturing roles. For example, Lilly's expanded $50 billion multi-year commitment includes a $6.5 billion facility in Houston and a $5 billion Virginia plant for antibody-drug conjugates, creating thousands of skilled jobs (^[2]) (^[3]). Construction roles (often 3–4 times higher in number) accompany them, but the skilled positions include engineers, process development scientists, and long-term manufacturing technicians.

Johnson & Johnson’s plan ($55B investment buildout) promises 500 permanent roles at a new North Carolina site (^[32]). Many of those jobs – mechanical and industrial engineers, chemists, microbiologists – are exactly the types of positions recruiting firms report difficulty filling due to generally low unemployment in STEM. In practical terms, these expansions have led to dozens of local hiring postings. For instance, the Amgen expansion in Ohio alone is recruiting 750 new employees (^[29]), including engineers and operators. State workforce agencies have organized job fairs in close coordination with pharma companies to find talent for these specific skill sets.

At the same time, political pressures can have unexpected outcomes. Even as most firms are adding jobs domestically, a few are restructuring. Novo Nordisk’s example is illuminating: it had aggressively doubled its global workforce from ~43,000 to ~77,000 amid the Wegovy boom (^[46]), including many U.S. manufacturing hires. However, by mid-2025 the company announced a hiring freeze and began trimming positions (notably in manufacturing technical and QC roles) to manage costs (^[48]). This suggests that demand for even high-value roles can be volatile if market conditions change (in Novo’s case, slowing volume growth). The lesson is that while structural trends (reshoring, biotech innovations) drive demand, individual company circumstances also matter.

Case Study: India as a Pharma Tech Hub

India’s role in the global pharma workforce has expanded dramatically. A series of recent announcements highlights this transformation. Sanofi is investing €400 million in its Hyderabad Global Capacity Centre (GCC) to double its workforce from 1,000 to 2,600 by 2026, specifically hiring “data scientists and engineers” for its digital teams (^[4]). Likewise, Amgen’s new Hyderabad biotech center (opened 2024) will focus on AI/data science; it expects to grow from 300 employees to about 2,000 by 2026 (^[42]). Merck doubled down too: it plans to expand its India headcount from ~1,800 to ~2,700 in one year, with an eye to “double that number” in a few years, including hires described as “digital innovators” at a new tech center (^[49]). Perhaps most striking, Bristol Myers Squibb announced in early 2024 that its new $100 million Hyderabad R&D facility will be the company’s largest outside the U.S., employing over 1,500 people by 2025, and will explicitly “leverage digital technologies and AI” in drug development (^[41]).

These announcements show that several multinational pharmaceutical companies are building technology, digital, and R&D capacity in India. They do not establish that the fastest-growing pharma jobs are in India, identify the skills most common in all job postings, or demonstrate a broader displacement of Western-based data-science roles. The examples are best interpreted as company-specific workforce and capability plans.

In parallel, India continues to grow as a clinical and manufacturing hub more broadly. Contract development organizations in Mumbai, Bangalore, and Hyderabad are expanding services, supporting life sciences growth projections (the Indian clinical trial market is expected to exceed $1.5 billion by 2025 (^[9])). Nearly half of the top 50 life sciences companies now have Global Capability Centers (GCCs) in India, with healthcare and life sciences accounting for over 15% of all GCC employees in the country (^[50]). GCCs are shifting from cost-efficiency centers to strategic innovation and regulatory science hubs. The convergence of biotech, data, and manufacturing roles in India is encapsulated by these case examples. Locally, universities and private institutes have responded: there is a surge in programs in biostatistics, bioinformatics, and digital health. Overall, the Indian case underscores that demand is in fact global – it is not only American or European companies hiring, but a shift to a more geographically diverse workforce.

Case Study: The Wegovy Effect – Specialized Hiring

The “Wegovy effect” (named for Novo Nordisk’s GLP-1 obesity drug) offers a microcosm of how demand for roles can spike and then recalibrate. In 2019–2024 Novo Nordisk nearly doubled its global employee count (^[46]), driven by the unparalleled success of Wegovy and its diabetes portfolio. This led to heavy hiring across R&D, manufacturing, and commercial divisions. In manufacturing, the Clayton, NC plant (one of the largest global sites for semaglutide production) saw many hires for technical roles. The newsroom analysis shows that many manufacturing technicians, QC analysts, and related staff were added to ramp up production (^[51]). On the clinical side, Novo ramped up trial operations when designing new indications (e.g. for obesity in new populations).

However, Novo Nordisk later announced a company-wide transformation plan. Under CEO Maziar Mike Doustdar, who succeeded Lars Fruergaard Jørgensen in August 2025, the company said the plan included a workforce reduction of around 9,000 positions and annualised savings of DKK 8 billion from 2026 onward (^[12]). Some of the roles being cut were precisely the technical manufacturing and quality positions hired during the boom (^[48]). In Denmark alone, 5,000 positions were cut. At the Clayton, NC plant, production-line and QC staff were among those laid off as sales projections became more conservative (^[48]). This illustrates how demand can be product-cycle dependent: when a product launches strongly, jobs (especially manufacturing and sales) expand quickly; if competition intensifies (from Eli Lilly’s Zepbound and cheaper alternatives), dramatic corrections follow.

The Wegovy case also highlights another phenomenon: private investment moves in the direction of pharma talent. Large hedge funds (seeking insight on giants like Novo) have begun hiring doctors, scientists and analysts to understand pharma pipelines (^[52]). While not pharma company roles per se, this trend underscores the overall premium on pharma expertise. Patients and public policy aside, the labor market value of pharma R&D knowledge is high, spilling over even into finance.

The demand patterns identified have several implications for the pharmaceutical industry’s future workforce. First, the skill transformation is clear: traditional lab and clinical backgrounds remain essential, but they increasingly pair with digital proficiency. A chemist today is ideally one who can also code; a clinical project manager now often needs to oversee digital endpoints and AI-driven trial tools. Educational programs are responding – see partnerships like Lilly-Purdue on AI (^[25]) – but there is a transitional gap. Companies may need to invest more in retraining and cross-disciplinary teams. This suggests that going forward, roles such as “Pharma Data Scientist” or “Computer-Aided Drug Designer” will transition from niche to mainstream.

Second, the geographic distribution of roles is shifting. While the U.S. and Europe remain major centers for high-value positions (e.g., top-tier management, regulatory headquarters), operational roles are globalizing. As the India case study shows, a significant portion of R&D and data roles can be fulfilled offshore. Manufacturing, while trending back to the U.S., is also expanding in Asia and Latin America (e.g., demand for vaccine production in Vietnam and Brazil). Companies will continue to balance costs and talent availability globally. Thus, multinational firms may adjust recruitment pipelines – hiring more software and data talent from tech hubs like Bangalore, and more manufacturing specialists in regions investing in life sciences infrastructure.

Third, technology will continue to reshape roles. AI is only in its early days in pharma. Upcoming tools – from large language models (LLMs) that can draft regulatory documents to advanced lab automation robots – could change job descriptions. For instance, clinical data entries and literature reviews might be partly automated by advanced AI next year, shifting human roles toward oversight and interpretation. Similarly, quality and compliance roles may evolve: real-time quality analytics will require personnel who can interpret statistical process control dashboards. Regulatory submissions might be partly auto-generated, but experts will be needed to validate them. Employers already cite “digital literacy” and adaptability as top requirements even for non-tech roles.

Another implication is the cycle of demand and restructuring. The 22,000+ layoffs across large pharma in 2025 – with Bristol Myers Squibb cutting ~2,200 positions, Bayer continuing a 12,000+ reduction, GSK trimming up to 350 R&D roles in early 2026, and Takeda laying off 243 field-based commercial employees (^[11]) – demonstrate that the industry undergoes simultaneous expansion and contraction. The Wegovy and pandemic examples highlight that hiring peaks and valleys will occur. Companies and policymakers must prepare pipelines of talent that can flex up when breakthroughs happen. Initiatives like flexible training programs or conditional hiring agreements can help mitigate sudden shortages. Governments in life-science hubs are taking note: for example, North Carolina has partnered to funnel engineering graduates into biotech manufacturing roles (partially prompted by Amgen and others expanding there).

Lastly, workforce wellbeing and diversity will remain important. Rapid expansion can strain workers (as seen in pharmacy burnout (^[10])). Companies may find that even if roles are in demand, they must invest in retention strategies. On diversity: as the talent pool globalizes, inclusion of underrepresented groups in STEM traineeships and global teams will be critical. Some firms have ESG and DEI (diversity, equity, inclusion) targets tied to workforce planning, which could influence hiring practices in the future.

In the long run, these trends suggest that pharma companies will hire as much for data-centric and engineering-centric skills as for pure chemistry/biology skills. Educational institutions, policymakers, and industry leaders should note this shift. Rock-bottom interest in pharmacy degree programs, for instance, may be countered (private sector initiatives like Walgreens’ tuition program (^[10]) reflect attempts to grow one segment of the pipeline). We may see more cross-training programs (e.g., engineers educated in pharmacology, biologists trained in coding). As one industry expert put it, pharma is hiring “T-shaped” professionals – deep in one area (say immunology) with broad digital fluency on top.

The pharmaceutical industry in early 2026 is characterized by simultaneous capacity-expansion announcements and workforce restructuring. Manufacturing, process and quality, data and AI, and clinical-development functions recur in the evidence reviewed, but the cited sources do not establish current demand rankings for individual roles. This results from a confluence of factors: multi-billion-dollar investments in domestic production (^[1]) (^[2]), the growing complexity of R&D pipelines (biologics, personalized medicine), and the digital transformation sweeping drug development (^[5]) (^[4]). Even within traditional roles, higher technical proficiency is being expected (e.g. “analytical chemists skilled in automated assays”).

The evidence is compelling: multiple company announcements promise thousands of jobs (^[2]) (^[14]), industry surveys indicate record hiring intent (^[13]), and labor analyses show regional growth in life science employment (^[15]) (^[16]). Moreover, the strategic case studies illustrate the real impact of these trends. For instance, U.S. policy pressures have sparked an unprecedented reshoring and consequent hiring surge in manufacturing (^[34]) (^[29]). Similarly, the rise of AI in pharma—from drug discovery to safety reporting—is contributing to the creation of new career tracks (^[44]) (^[24]).

Going forward, we can anticipate that pharmaceutical roles will continue to intertwine science and technology. Deep knowledge of biology or chemistry will be necessary but not always sufficient; computational literacy will be equally important. Regulatory and quality functions will command sophisticated policy and data-analysis skills. Employment will remain strong in hubs that combine scientific infrastructure with tech talent (e.g. Boston, RTP, Bangalore). Conversely, areas slow to adapt (purely traditional retail pharmacy, for instance) may face labor shortfalls.

In summary, the evidence reviewed identifies biotech/process engineering, manufacturing operations, analytical science, data/AI, clinical development, and regulatory/quality as important capability areas. It does not establish a definitive ranking of the most in-demand individual pharma roles. Companies explicitly acknowledge this mix in their hiring plans (^[1]) (^[4]). As the industry continues to evolve, workers and educators alike should prepare for these roles: they represent both the present reality and the future direction of pharmaceutical careers.